| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/03/2023 | 87.5% | Needham | $22 → $15 | Maintains | Buy |
| 09/08/2023 | 75% | B of A Securities | $23 → $14 | Downgrades | Buy → Neutral |
| 08/07/2023 | 1087.5% | HC Wainwright & Co. | $100 → $95 | Maintains | Buy |
| 08/04/2023 | 175% | Needham | → $22 | Reiterates | Buy → Buy |
| 07/21/2023 | 87.5% | Morgan Stanley | $27 → $15 | Maintains | Equal-Weight |
| 07/21/2023 | 250% | Goldman Sachs | $51 → $28 | Maintains | Buy |
| 07/21/2023 | 412.5% | Barclays | $59 → $41 | Maintains | Overweight |
| 07/20/2023 | 175% | Needham | $32 → $22 | Maintains | Buy |
| 07/20/2023 | 1150% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy |
| 05/05/2023 | 300% | Needham | → $32 | Reiterates | → Buy |
| 04/19/2023 | 300% | Needham | → $32 | Reiterates | → Buy |
| 04/04/2023 | 237.5% | Morgan Stanley | $25 → $27 | Maintains | Equal-Weight |
| 03/06/2023 | 1150% | HC Wainwright & Co. | $125 → $100 | Maintains | Buy |
| 03/06/2023 | 325% | JP Morgan | $35 → $34 | Upgrades | Neutral → Overweight |
| 02/24/2023 | 300% | Needham | → $32 | Reiterates | → Buy |
| 02/23/2023 | 562.5% | Goldman Sachs | $41 → $53 | Maintains | Buy |
| 02/21/2023 | 562.5% | Goldman Sachs | $41 → $53 | Upgrades | Neutral → Buy |
| 01/27/2023 | 437.5% | SVB Leerink | $45 → $43 | Maintains | Outperform |
| 01/27/2023 | 275% | Morgan Stanley | $18 → $30 | Upgrades | Underweight → Equal-Weight |
| 11/04/2022 | 125% | Morgan Stanley | $15 → $18 | Maintains | Underweight |
| 11/04/2022 | 300% | Needham | $35 → $32 | Maintains | Buy |
| 11/04/2022 | 462.5% | SVB Leerink | $40 → $45 | Maintains | Outperform |
| 09/14/2022 | 400% | SVB Leerink | → $40 | Initiates Coverage On | → Outperform |
| 09/09/2022 | 87.5% | Morgan Stanley | → $15 | Initiates Coverage On | → Underweight |
| 05/12/2022 | 1462.5% | HC Wainwright & Co. | $200 → $125 | Maintains | Buy |
| 05/06/2022 | 337.5% | Needham | $45 → $35 | Maintains | Buy |
| 03/30/2022 | 2400% | HC Wainwright & Co. | $300 → $200 | Maintains | Buy |
| 03/28/2022 | 462.5% | Needham | $80 → $45 | Maintains | Buy |
| 03/03/2022 | 250% | Baird | $36 → $28 | Upgrades | Underperform → Neutral |
| 12/21/2021 | 350% | Baird | → $36 | Downgrades | Neutral → Underperform |
| 12/21/2021 | 3650% | HC Wainwright & Co. | $200 → $300 | Maintains | Buy |
| 11/30/2021 | 2400% | HC Wainwright & Co. | $135 → $200 | Maintains | Buy |
| 10/25/2021 | 362.5% | JP Morgan | $29 → $37 | Upgrades | Underweight → Neutral |
| 09/22/2021 | 675% | Goldman Sachs | $64 → $62 | Downgrades | Buy → Neutral |
| 08/06/2021 | 787.5% | Barclays | $96 → $71 | Maintains | Overweight |
| 03/11/2021 | 900% | Needham | $75 → $80 | Maintains | Buy |
| 03/08/2021 | 1587.5% | HC Wainwright & Co. | $125 → $135 | Maintains | Buy |
| 03/02/2021 | 837.5% | Needham | $62 → $75 | Maintains | Buy |
| 01/27/2021 | 275% | JP Morgan | → $30 | Downgrades | Neutral → Underweight |
| 01/20/2021 | 1462.5% | HC Wainwright & Co. | $100 → $125 | Maintains | Buy |
| 10/07/2020 | 1150% | HC Wainwright & Co. | $80 → $100 | Maintains | Buy |
| 10/05/2020 | 587.5% | B of A Securities | → $55 | Initiates Coverage On | → Buy |
| 09/21/2020 | 900% | HC Wainwright & Co. | $75 → $80 | Maintains | Buy |
| 09/14/2020 | 575% | Goldman Sachs | $48 → $54 | Upgrades | Neutral → Buy |
| 09/11/2020 | 262.5% | JP Morgan | $30 → $29 | Upgrades | Underweight → Neutral |
| 08/20/2020 | 675% | Needham | → $62 | Initiates Coverage On | → Buy |
| 03/27/2020 | 150% | Baird | $17 → $20 | Maintains | Underperform |
| 03/19/2020 | 225% | JP Morgan | → $26 | Downgrades | Neutral → Underweight |
| 03/13/2020 | — | Goldman Sachs | Downgrades | Buy → Neutral | |
| 02/04/2020 | 225% | JP Morgan | $25 → $26 | Downgrades | Overweight → Neutral |
| 11/14/2019 | 112.5% | Baird | → $17 | Initiates Coverage On | → Neutral |
| 11/05/2019 | 212.5% | Barclays | → $25 | Initiates Coverage On | → Overweight |
| 11/05/2019 | 362.5% | Goldman Sachs | → $37 | Initiates Coverage On | → Buy |
| 11/05/2019 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/05/2019 | 212.5% | JP Morgan | → $25 | Initiates Coverage On | → Overweight |
What is the target price for Vir Biotechnology (VIR)?
The latest price target for Vir Biotechnology (NASDAQ: VIR) was reported by Needham on November 3, 2023. The analyst firm set a price target for $15.00 expecting VIR to rise to within 12 months (a possible 87.50% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vir Biotechnology (VIR)?
The latest analyst rating for Vir Biotechnology (NASDAQ: VIR) was provided by Needham, and Vir Biotechnology maintained their buy rating.
When is the next analyst rating going to be posted or updated for Vir Biotechnology (VIR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vir Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vir Biotechnology was filed on November 3, 2023 so you should expect the next rating to be made available sometime around November 3, 2024.
Is the Analyst Rating Vir Biotechnology (VIR) correct?
While ratings are subjective and will change, the latest Vir Biotechnology (VIR) rating was a maintained with a price target of $22.00 to $15.00. The current price Vir Biotechnology (VIR) is trading at is $8.00, which is out of the analyst's predicted range.